| Year |
Citation |
Score |
| 2023 |
de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews GM, Barwick BG, Gupta VA, Dupéré-Richer D, Yamano S, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Ishiguro K, Meyers RM, et al. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nature Cancer. 4: 754-773. PMID 37237081 DOI: 10.1038/s43018-023-00550-x |
0.329 |
|
| 2021 |
Sheffer M, Lowry E, Beelen N, Borah M, Amara SN, Mader CC, Roth JA, Tsherniak A, Freeman SS, Dashevsky O, Gandolfi S, Bender S, Bryan JG, Zhu C, Wang L, et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nature Genetics. PMID 34253920 DOI: 10.1038/s41588-021-00889-w |
0.335 |
|
| 2020 |
Dashevsky O, De Matos Simoes R, Shirasaki R, Sheffer M, Dhimolea E, Gandolfi S, Tang H, Downey-Kopyscinski SL, Bariteau M, Sorrell J, Glassner B, Doench J, Boise LH, Licht JD, Culhane A, et al. Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms Blood. 136: 36-36. DOI: 10.1182/BLOOD-2020-142651 |
0.358 |
|
| 2020 |
De Matos Simoes R, Shirasaki R, Tang H, Yamano S, Barwick BG, Gandolfi S, Dhimolea E, Downey-Kopyscinski SL, Dashevsky O, Glassner B, Sheffer M, Kansara D, Bariteau M, Sorrell J, Gupta V, et al. POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma Blood. 136: 18-19. DOI: 10.1182/blood-2020-142580 |
0.335 |
|
| 2020 |
Sheffer M, Mitsiades C. 36 Molecular events regulating solid tumor cell responses to natural killer cells Journal For Immunotherapy of Cancer. 8: A37-A37. DOI: 10.1136/jitc-2020-sitc2020.0036 |
0.375 |
|
| 2019 |
De Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews G, Yiguo H, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Dempster J, Meyers RM, Bryan J, McFarland JM, Brueggenthies J, Tang H, et al. Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma Blood. 134: 4407-4407. DOI: 10.1182/Blood-2019-130901 |
0.463 |
|
| 2019 |
Gandolfi S, Sheffer M, Dufva O, Saeed K, Lowry E, Dashevsky O, Shirasaki R, Simoes RDM, Roth J, Romee R, Mustjoki S, Mitsiades CS. Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled DNA-Barcoded Cell Line Panels Blood. 134: 620-620. DOI: 10.1182/Blood-2019-130793 |
0.396 |
|
| 2019 |
Shirasaki R, Gandolfi S, De Matos Simoes R, Matthews GM, Buckley D, Raja J, Sievers QL, Dashevsky O, Poarch H, Tang H, Bariteau M, Sheffer M, Downey-Kopyscinski SL, Hengeveld P, Glassner B, et al. Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins Blood. 134: 318-318. DOI: 10.1182/Blood-2019-130549 |
0.402 |
|
| 2019 |
Dufva O, Saeed K, Gandolfi S, Sheffer M, Klievink J, Pölönen P, Hannunen T, Ilander M, Ellonen P, Kankainen M, Lee DA, Mitsiades CS, Mustjoki S. CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers Blood. 134: 3597-3597. DOI: 10.1182/Blood-2019-129837 |
0.36 |
|
| 2019 |
Tang H, Shirasaki R, Simoes RDM, Gandolfi S, Dashevsky O, Downey-Kopyscinski SL, Glassner B, Sheffer M, Bariteau M, Doench JG, Mitsiades CS. Functional Characterization of Genes Driving Enhanced Biological Aggressiveness of Myeloma Cells: Identification of Novel and Understudied Drivers of Myeloma Blood. 134: 313-313. DOI: 10.1182/Blood-2019-128919 |
0.405 |
|
| 2019 |
Gandolfi S, Sheffer M, Lowry E, Dashevsky O, Shirasaki R, Simoes RdM, Romee R, Roth J, Mitsiades C. Molecular markers of MM cell sensitivity and resistance to Natural Killer cells: implications for anti-MM immunotherapy Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.281 |
0.356 |
|
| 2019 |
Tang H, Shirasaki R, Gandolfi S, Simoes RdM, Dashevsky O, Glassner BJ, Downey-Kopyscinski S, Sheffer M, Bariteau M, Doench J, Mitsiades C. Gain-of-function studies with CRISPR-based transcriptional activation at endogenous genomic loci reveals genes with critical roles for myeloma cells Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.074 |
0.405 |
|
| 2018 |
Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, et al. SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Science Signaling. 11. PMID 29382783 DOI: 10.1126/Scisignal.Aan0949 |
0.375 |
|
| 2018 |
Tang H, Simoes RDM, Shirasaki R, Dashevsky O, Glassner B, Downey-Kopyscinski SL, Gandolfi S, Sheffer M, Bariteau M, Doench JG, Mitsiades CS. CRISPR Activation Screen for HDAC Inhibitor Resistance Blood. 132: 3958-3958. DOI: 10.1182/Blood-2018-99-119044 |
0.454 |
|
| 2018 |
Gandolfi S, Sheffer M, Lowry E, Dashevsky O, Shirasaki R, Simoes RDM, Mitsiades CS. Identification of Molecular Markers of Tumor Cell Sensitivity and Resistance to Natural Killer Cells through Genome-Wide CRISPR Activation and CRISPR Editing Screens in Multiple Myeloma Cell Lines: Implications for Anti-Myeloma Immunotherapy Blood. 132: 1115-1115. DOI: 10.1182/Blood-2018-99-118736 |
0.475 |
|
| 2018 |
Tang H, Simoes RDM, Shirasaki R, Dashevsky O, Glassner B, Downey-Kopyscinski SL, Gandolfi S, Sheffer M, Bariteau M, Doench JG, Mitsiades CS. CRISPR Activation Screen for Drivers of MM Cell Proliferation Blood. 132: 3197-3197. DOI: 10.1182/Blood-2018-99-118712 |
0.493 |
|
| 2018 |
Shirasaki R, Gandolfi S, De Matos Simoes R, Matthews G, Buckley D, Dashevsky O, Downey-Kopyscinski SL, Tang H, Sheffer M, Dhimolea E, Glassner B, Bariteau M, Sorrell J, Bruggenthies JB, Sievers Q, et al. CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias Blood. 132: 1367-1367. DOI: 10.1182/Blood-2018-99-116232 |
0.438 |
|
| 2018 |
De Matos Simoes R, Shirasaki R, Tang H, Sheffer M, Dashevsky O, Gandolfi S, Dhimolea E, Bariteau M, Licht JD, Glassner B, Groen RW, Levy J, Auclair D, Vazquez F, Tsherniak A, et al. Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma Blood. 132: 189-189. DOI: 10.1182/Blood-2018-189 |
0.469 |
|
| 2018 |
Shirasaki R, Gandolfi S, Simoes RDM, Matthews G, Downey S, Dashevsky O, Huihui T, Sheffer M, Dhimolea E, Bariteau M, Sorrel J, Kwiatkowski N, Zhang T, Gray N, Mitsiades C. Abstract 2834: Genomewide CRISPR studies of sequential treatment with CRBN-based degronimids: Insights into the molecular evolution of treatment resistance in myeloma and beyond Cancer Research. 78: 2834-2834. DOI: 10.1158/1538-7445.Am2018-2834 |
0.458 |
|
| 2017 |
Sheffer M, Wieten L, Yu C, Yu Y, Dashevsky O, Lowry E, Roth J, Tsherniak A, Mader CC, Bender S, Bryan J, Zhu C, Wang L, Simoes RDM, Gandolfi S, et al. Identification and Validation of Molecular Markers of Tumor Cell Resistance to Natural Killer Cells through CRISPR-Based Screens and Large-Scale Phenotypic Screens of Pooled Tumor Cell Lines Blood. 130: 623-623. DOI: 10.1182/Blood.V130.Suppl_1.623.623 |
0.447 |
|
| 2017 |
Shirasaki R, Tamas C, Matthews G, Simoes RDM, Sarkar S, Dashevsky O, Yiguo H, Sorrell J, Sheffer M, Dhimolea E, Bariteau M, Glassner B, Culhane A, Groen RW, Mitsiades CS. In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a Humanized Bone Marrow-like Microenvironment Blood. 130: 4414-4414. DOI: 10.1182/Blood.V130.Suppl_1.4414.4414 |
0.322 |
|
| 2017 |
Gandolfi S, Dashevsky O, Simoes RDM, Matthews G, Shirasaki R, Sheffer M, Mitsiades CS. Long-Term Interactions with Bone Marrow Stromal Cells Alter the Molecular Dependencies of Myeloma Cells: Insights from Genomewide CRISPR-Based Functional Genomic Screens Blood. 130: 3028-3028. DOI: 10.1182/Blood.V130.Suppl_1.3028.3028 |
0.486 |
|
| 2017 |
Matthews GM, Simoes RdM, Hu Y, Sheffer M, Dashevsky O, Dhimolea E, Hengeveld PJ, Glassner BJ, Gandolfi S, Bariteau MA, Sievers Q, Ebert BL, Vazquez F, Culhane A, Mitsiades CS. Abstract LB-118: Characterization of lineage vs. context-dependent essential genes in multiple myeloma using CRISPR-Cas9 genome editing Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-118 |
0.352 |
|
| 2016 |
Bublik DR, Bursać S, Sheffer M, Oršolić I, Shalit T, Tarcic O, Kotler E, Mouhadeb O, Hoffman Y, Fuchs G, Levin Y, Volarević S, Oren M. Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America. PMID 27994142 DOI: 10.1073/Pnas.1614876114 |
0.351 |
|
| 2016 |
Matthews GM, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, Sorrell JD, Mitsiades CS. NF-κB dysregulation in multiple myeloma. Seminars in Cancer Biology. PMID 27544796 DOI: 10.1016/J.Semcancer.2016.08.005 |
0.332 |
|
| 2016 |
Simoes RDM, Matthews GM, Hu Y, Glassner B, Bariteau MA, Sheffer M, Shirasaki R, Mitsiades CS. Integrated Evaluation of Results from Genome-Wide Association Studies and Crispr/Cas9-Based Functional Genomics in Myeloma: Implications for Cell-Autonomous Vs. Non-Autonomous Role of Candidate Genes in Myeloma Pathophysiology Blood. 128: 486-486. DOI: 10.1182/Blood.V128.22.486.486 |
0.476 |
|
| 2016 |
Matthews GM, De Matos Simoes R, Hu Y, Sheffer M, Dhimolea E, Hengeveld PJ, Bariteau MA, Glassner B, Sievers Q, Ebert BL, Gandolfi S, Awate P, Tang H, Vazquez F, Culhane A, et al. Characterization of Lineage Vs. Context-Dependent Essential Genes in Multiple Myeloma Using Crispr/Cas9 Genome Editing Blood. 128: 119-119. DOI: 10.1182/Blood.V128.22.119.119 |
0.478 |
|
| 2016 |
Matthews GM, Gandolfi S, Bruggentheis J, De Matos Simoes R, Buckley DL, Hu Y, Sheffer M, Poarch H, Bradner JE, Mitsiades CS. BET Bromodomain Degradation As a Therapeutic Strategy in Multiple Myeloma Blood. 128: 1062-1062. DOI: 10.1182/Blood.V128.22.1062.1062 |
0.417 |
|
| 2016 |
Matthews GM, Hu Y, Sheffer M, Hengeveld PJ, Buckley DL, Bariteau MA, Poarch H, Bradner JE, Mitsiades CS. Abstract 4713: BET bromodomain degradation as a therapeutic strategy in drug-resistant multiple myeloma Cancer Research. 76: 4713-4713. DOI: 10.1158/1538-7445.Am2016-4713 |
0.409 |
|
| 2015 |
Dhimolea E, King E, Sheffer M, Hu Y, Awate PP, Sarkar S, Matthews GM, Murnane M, Bariteau MA, Aftab BT, Mitsiades CS. Constitutive Vs. Stroma-Induced Kinase Dependencies in Myeloma Cells: Functional Mapping Using Small Molecule Inhibitors As Chemical Probes Blood. 126: 3709-3709. DOI: 10.1182/Blood.V126.23.3709.3709 |
0.398 |
|
| 2015 |
Hengeveld PJ, Matthews GM, Hu Y, Sheffer M, Bariteau MA, Poarch HI, Dhimolea E, Mitsiades CS. Systematic Evaluation of Preclinical Genetically Determined Vs. Stochastic/Transient Resistance to High-Dose Melphalan Treatment in Multiple Myeloma Blood. 126: 2484-2484. DOI: 10.1182/Blood.V126.23.2484.2484 |
0.414 |
|
| 2015 |
Dhimolea E, King E, Rogulin V, Awate PP, Sheffer M, Hu Y, Sarkar S, Murnane M, Bariteau MA, Aftab B, Mitsiades CS. Functional mapping of multiple myeloma kinome with library of small molecule inhibitors Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.207 |
0.367 |
|
| 2015 |
Hu Y, Sheffer M, Matthews GM, Hengeveld P, Shalem O, Zhang F, Dhimolea E, Sarkar S, Bariteau M, Aftab B, Groen R, Mitsiades CS. Genome-scale CRISPR-Cas9 knockout studies to characterize the mechanisms of myeloma cell treatment resistance. Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.172 |
0.34 |
|
| 2014 |
Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proceedings of the National Academy of Sciences of the United States of America. 111: 7006-11. PMID 24778235 DOI: 10.1073/Pnas.1320428111 |
0.327 |
|
| 2014 |
Dhimolea E, King E, Sheffer M, Hu Y, Sarkar S, Murnane M, Bariteau MA, Aftab BT, Mitsiades CS. Functional Mapping of Multiple Myeloma Kinome Using a Small Molecule Inhibitor Library Blood. 124: 3642-3642. DOI: 10.1182/Blood.V124.21.3642.3642 |
0.373 |
|
| 2014 |
Dhimolea E, King E, Kastritis E, McMillin DW, Delmore JE, Negri JM, Jacobs HM, Hayes CA, Sheffer M, Hu Y, Sarkar S, Groen RWJ, Bariteau MA, Aftab BT, Mitsiades CS. Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications Blood. 124: 276-276. DOI: 10.1182/Blood.V124.21.276.276 |
0.386 |
|
| 2014 |
Sheffer M, Hu Y, Shalem O, Sanjana N, Dhimolea E, Sarkar S, Bariteau MA, Aftab BT, Groen RWJ, Zhang F, Mitsiades CS. Genome-Scale Crispr-Cas9 Knockout Studies Reveal Mutifactorial and Functionally Overlapping Mechanisms of Myeloma Cell Resistance to Proteasome Inhibition Blood. 124: 273-273. DOI: 10.1182/Blood.V124.21.273.273 |
0.451 |
|
| 2013 |
Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E, Domany E, Ben-Ze'ev A. c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. Cancer Research. 73: 5754-63. PMID 24008320 DOI: 10.1158/0008-5472.Can-13-0576 |
0.588 |
|
| 2013 |
Kim SH, Wang D, Park YY, Katoh H, Margalit O, Sheffer M, Wu H, Holla VR, Lee JS, DuBois RN. HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Letters. 341: 159-65. PMID 23916472 DOI: 10.1016/J.Canlet.2013.07.028 |
0.422 |
|
| 2013 |
Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 6388-93. PMID 23547110 DOI: 10.1073/Pnas.1219651110 |
0.547 |
|
| 2013 |
Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, Sheffer M, Howell M, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 494: 492-6. PMID 23446422 DOI: 10.1038/Nature11935 |
0.371 |
|
| 2013 |
Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller M, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, Sheffer M, Howell M, et al. Corrigendum: Replication stress links structural and numerical cancer chromosomal instability Nature. 500: 490-490. DOI: 10.1038/Nature12369 |
0.304 |
|
| 2012 |
Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, Garufi A, Rechavi G, Givol D, D'Orazi G. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biology & Therapy. 13: 198-205. PMID 22236966 DOI: 10.4161/Cbt.13.4.18694 |
0.385 |
|
| 2012 |
Burrell RA, McClelland SE, Endesfelder D, Rowan A, Schenk A, Sheffer M, Shaikh N, Domingo E, Kschischo M, Domany E, Downward J, Tomlinson I, Swanton C. Abstract 3105: Chromosome 18q encodes a chromosomal instability suppressor locus in colorectal cancer Cancer Research. 72: 3105-3105. DOI: 10.1158/1538-7445.Am2012-3105 |
0.541 |
|
| 2011 |
Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, D'Orazi G. Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget. 2: 1191-202. PMID 22202117 DOI: 10.18632/Oncotarget.395 |
0.615 |
|
| 2011 |
Sagiv E, Sheffer M, Kazanov D, Shapira S, Naumov I, Kraus S, Domany E, Arber N. Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. Digestion. 84: 169-84. PMID 21546775 DOI: 10.1159/000322688 |
0.519 |
|
| 2009 |
Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 7131-6. PMID 19359472 DOI: 10.1073/Pnas.0902232106 |
0.551 |
|
| 2009 |
Sagiv E, Sheffer M, Kazanov D, Shapira S, Naumov I, Kraus S, Domany E, Arber N. S1971 Celecoxib Selectively Targets Genes and Pathways Involved in Inflammation and Malignant Transformation in Tumor But Not Normal Cells Gastroenterology. 136: A-304. DOI: 10.1016/S0016-5085(09)61387-1 |
0.571 |
|
| 2007 |
Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze'ev A. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Research. 67: 7703-12. PMID 17699774 DOI: 10.1158/0008-5472.Can-07-0991 |
0.587 |
|
| 2005 |
Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Crémoux P, de La Rochefordière A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany E, Sastre-Garau X. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene. 24: 7094-104. PMID 16007141 DOI: 10.1038/Sj.Onc.1208854 |
0.542 |
|
| Show low-probability matches. |